ArticleMethods in molecular biology (Clifton, N.J.)2026
Isolation and Characterization of Mesenchymal Stem Cells from Human Umbilical Cord Tissue.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells (MSCs) were first described over 30 years ago as multipotent stromal cells that can self-renew and differentiate into bone, cartilage, and fat tissues. MSCs have numerous functions, such as modulating the immune system, regulating inflammation, promoting wound healing, improving engraftment following hematopoietic transplant, and providing a supportive microenvironment for hematopoietic stem cells. Human umbilical cord tissue, which is more easily obtained than bone marrow aspirates, contains a population of MSCs. These cells can enhance thrombopoiesis in umbilical cord blood-derived megakaryocytes, leading to the production of platelets with low baseline activation levels. Scaled-up methods to enhance platelet production in vitro while maintaining a low activation state would benefit transfusion medicine and circumvent frequent platelet donor shortages. Here, we outline a protocol to isolate and expand MSCs from human umbilical cord tissue and characterize their cell surface protein expression by flow cytometry, self-renewal potential by colony-forming assay, and tri-lineage differentiation capacity.
Indexed as
Identifiers
42681424What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.